查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717824

微量残存疾病检测市场按产品类型、检测方法、应用领域和最终用户划分－2025-2030 年全球预测

Minimal Residual Disease Testing Market by Product Type, Test Techniques, Application Areas, End-User Vertical - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计微量残存疾病检测市场规模在 2024 年将达到 18.7 亿美元，到 2025 年将以 11.18% 的复合年增长率增长至 20.8 亿美元，到 2030 年将达到 35.4 亿美元。

主要市场统计数据
基准年2024年 18.7亿美元
预计年份：2025年 20.8亿美元
预测年份 2030 35.4亿美元
复合年增长率（%） 11.18%

微量残存疾病（MRD）检测已成为各种癌症早期发现和持续监测的重要工具。近年来，临床和研究界已经认识到需要检测治疗期间或治疗后残留的哪怕是微量的恶性细胞。 MRD 测试具有出色的敏感性，使临床医生能够客製化治疗通讯协定、衡量治疗效果并可能改善整体患者预后。

这种创新的诊断技术弥合了传统成像技术与先进分子生物学方法之间的差距。透过利用测量细胞和分子水平变化的技术，MRD 测试为医疗保健提供者提供了可操作的资讯。作为精准肿瘤学的综合工具，该方法不仅重新定义了患者照护的范式，也为未来的研究建立了坚实的框架。本简报深入探讨了重塑医疗诊断这一关键领域的变革、市场区隔见解、区域动态和主要企业。

改变微量残存疾病检测市场

在过去的十年中，由于技术的突破和对肿瘤生物学理解的加深，MRD 检测领域取得了显着的发展。更灵敏的检测技术和下一代方法的出现重新定义了早期癌症诊断的标准。这项革命性的变化为治疗白血病、淋巴瘤、多发性骨髓瘤和固体癌等癌症所必需的早期疗育策略铺平了道路。

这些转变超越了测试的分析敏感性，并延伸至整个医疗保健生态系统的运作架构。先进的自动化和数位化整合正在简化临床实验室的工作流程，缩短週转时间并提高对测试结果的信心。此外，数据分析和计算生物学的进步增强了医生追踪病情进展和即时调整治疗的能力。这种转变的背后是多学科研究的融合、技术投资以及对以患者为中心的解决方案的整体承诺。

此外，监管发展和标准化工作正在提高 MRD 测试的可靠性，并确保这些技术与全球医疗标准相协调。这些因素的汇合预计将扩大市场基础，加速临床应用，并最终重新定义全球癌症治疗中采用的诊断方法。

关键细分市场洞察

对市场动态的详细分析揭示了多方面的细分，这对于理解 MRD 测试的当前和未来发展轨迹至关重要。市场已根据产品类型进行了研究，其中仪器、试剂和试剂套件以及软体服务都发挥着至关重要的作用。仪器为灵敏检测提供了技术支撑，试剂套件则保证了分析结果的准确性。此外，软体和服务有助于数据处理和结果解释，从而加强患者管理。

透过测试技术进一步细分，突显了流式细胞技术、次世代定序（NGS）和聚合酵素链锁反应（PCR）的重要性。每种技术都在不同的临床情况下提供可靠的结果。流式细胞技术因其在处理大量细胞群体时的速度和效率而继续受到青睐，而NGS则因其在检测基因异常方面无与伦比的灵敏度而受到称讚。 PCR 因其在扩增和检测过程中的良好记录，仍然是可靠的基础。

临床领域主要集中在白血病、淋巴瘤、多发性骨髓瘤和固态肿瘤，并根据应用领域进一步细分。这种细分凸显了癌症类型的多样性，需要一系列客製化的调查方法来满足特定的诊断和预后需求。在这些不同的应用中准确检测残留疾病强化了采用复杂且可自订的测试方法的必要性。

按最终用户细分包括学术研究机构、生物製药公司、诊断实验室和医院。每个部分都有其自身的特点，包括研究能力、业务需求和财务限制方面的要求。学术和研究机构专注于开发新通讯协定和阐明疾病机制，而生物製药公司和诊断实验室则专注于检验临床疗效和业务效率。同时，医院处于患者护理的最前沿，希望将 MRD 检测作为个人化治疗计划的常规要素。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 对早期检测和准确预后评估的需求日益增加
      • 精准医疗投资的增加推动了对个人化微量残存疾病检测的关注
      • 诊断创新推动微量残存疾病检测的成长
    • 限制因素
      • 测试和设备相关高成本
    • 机会
      • 透过探索微量残存疾病检测技术并将其整合到多疾病诊断解决方案中来扩展产品组合
      • 与生物技术公司合作，创新并开发更有效的微量残存疾病检测检测套组
    • 任务
      • 监管复杂且核准流程冗长
  • 市场区隔分析
    • 产品类型：仪器的进步提高了肿瘤诊断的准确性
    • 最终用户：学术研究在推进微量残存疾病检测技术中的作用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章微量残存疾病检测市场（依产品类型）

  • 介绍
  • 装置
  • 试剂和套件
  • 软体和服务

第七章微量残存疾病检测市场（依检测方法）

  • 介绍
  • 流式细胞技术
  • 下一代定序（NGS）
  • 聚合酵素链锁反应（PCR）

第八章微量残存疾病检测市场（依应用）

  • 介绍
  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 固态肿瘤

第九章微量残存疾病检测市场（依最终用户划分）

  • 介绍
  • 学术研究所
  • 生物製药公司
  • 诊断实验室
  • 医院

10.美洲微量残存疾病检测市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区微量残存疾病检测市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲微量残存疾病检测市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Adaptive BIoTechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis BV
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.
Product Code: MRR-961BA04A2E6C

The Minimal Residual Disease Testing Market was valued at USD 1.87 billion in 2024 and is projected to grow to USD 2.08 billion in 2025, with a CAGR of 11.18%, reaching USD 3.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.08 billion
Forecast Year [2030] USD 3.54 billion
CAGR (%) 11.18%

Minimal Residual Disease (MRD) testing has emerged as a critical tool in the early detection and continuous monitoring of various cancers. In recent years, the clinical and research communities have recognized the necessity of detecting even minute traces of malignant cells that remain during or after treatment. MRD testing offers an exceptional sensitivity that can enable clinicians to tailor treatment protocols, gauge therapeutic effectiveness, and potentially improve overall patient outcomes.

This innovative diagnostic approach bridges the gap between conventional imaging methodologies and advanced molecular techniques. By leveraging technologies that measure changes at the cellular and molecular level, MRD testing empowers healthcare providers with actionable intelligence. As an integrative tool in precision oncology, this method has not only redefined patient care paradigms but also established a robust framework for future research. In this summary, we delve into the transformative shifts, market segmentation insights, regional dynamics, and leading companies that are reshaping this crucial segment of healthcare diagnostics.

Transformative Shifts in the Testing Landscape

Over the past decade, the realm of MRD testing has witnessed a significant evolution driven by breakthroughs in technology and a growing understanding of tumor biology. The advent of more sensitive detection techniques and next-generation methodologies has redefined the standards for early cancer diagnostics. This revolutionary shift is paving the way for early intervention strategies that are critical in managing cancers such as leukemia, lymphoma, multiple myeloma, and solid tumors.

These transformative changes are not limited to the analytical sensitivity of the tests but also extend to the operational framework across healthcare ecosystems. Advanced automation and digital integration have streamlined the workflow in clinical laboratories, reducing turnaround times and improving the reliability of test outcomes. Moreover, improvements in data analytics and computational biology are augmenting the ability of physicians to track disease progression and adjust treatments in real time. The catalyst behind these shifts has been a convergence of interdisciplinary research, investment in technology, and an overarching commitment to patient-centric solutions.

In addition, regulatory advances and standardization efforts are bolstering the credibility of MRD testing, ensuring that these techniques are harmonized with global healthcare standards. This confluence of elements is expected to expand the market footprint, stimulate clinical adoption, and ultimately redefine the diagnostic approaches employed in oncological care globally.

Key Segmentation Insights

An in-depth analysis of the market dynamics reveals a multi-faceted segmentation that is fundamental in understanding the current and future trajectories of MRD testing. The market is studied based on product type where instruments, reagents and kits, and software and services each play a crucial role. Instruments provide the technological backbone for sensitive detection, while reagents and kits ensure the precision of analytical results. Complementarily, software and services are instrumental in data processing and result interpretation, driving enhanced patient management.

Further segmentation based on test techniques has highlighted the importance of flow cytometry, next-generation sequencing (NGS), and polymerase chain reaction (PCR). Each technique has carved its niche in delivering reliable results under different clinical scenarios. Flow cytometry continues to be favored for its speed and efficiency in handling large cell populations, whereas NGS is celebrated for its unparalleled sensitivity in detecting genetic aberrations. PCR remains a reliable cornerstone due to its proven track record in amplification and detection processes.

In the clinical realm, analysis segments further by application area, focusing on leukemias, lymphomas, multiple myelomas, and solid tumors. This segmentation underscores that the diversity of cancer types has necessitated a range of tailored methodologies to suit specific diagnostic and prognostic needs. The precise detection of residual disease in these varied applications reinforces the imperative of adopting sophisticated and customizable testing approaches.

The segmentation by end-user vertical encompasses academic and research institutes, biopharmaceutical companies, diagnostic laboratories, and hospitals. Each of these segments is characterized by unique requirements with respect to research capabilities, operational demands, and financial constraints. While academic and research institutions focus on pioneering novel protocols and understanding disease mechanisms, biopharmaceutical companies and diagnostic laboratories are geared towards validating clinical efficacy and operational efficiency. Hospitals, on the other hand, are at the frontline of patient care, looking to integrate MRD testing as a routine component in personalized treatment plans.

Based on Product Type, market is studied across Instruments, Reagents & Kits, and Software & Services.

Based on Test Techniques, market is studied across Flow Cytometry, Next-Generation Sequencing (NGS), and Polymerase Chain Reaction (PCR).

Based on Application Areas, market is studied across Leukemia, Lymphoma, Multiple Myeloma, and Solid Tumors.

Based on End-User Vertical, market is studied across Academic & Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories, and Hospitals.

Key Regional Insights

The geographical landscape of MRD testing is as diverse as its technical components. Market dynamics vary significantly across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust clinical infrastructure coupled with a high adoption rate of innovative diagnostic techniques contributes to a thriving MRD market. Significant investments, particularly in research institutions and healthcare facilities, are fueling the demand for cutting-edge testing modalities.

In Europe, Middle East & Africa, integrated regulatory frameworks and a strong emphasis on clinical research are driving market evolution. This region is characterized by an intermingling of state-of-the-art healthcare facilities and progressive clinical practices, which are steadily increasing the adoption of MRD diagnostics. Regulatory harmonization and government-sponsored initiatives aim to standardize diagnostic procedures, thereby ensuring a consistent and reliable approach to MRD testing.

Asia-Pacific remains one of the most promising regions, given its rapid economic growth, expanding healthcare infrastructure, and increasing investments in research and development. The region's growing focus on personalized medicine coupled with rising awareness about early disease detection is accelerating market growth. Regional differences in demographics and disease prevalence are shaping the market, making local adaptation of global MRD testing strategies a key competitive differentiator.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

A detailed exploration of the market reveals active participation by a range of leading companies that are spearheading advancements in MRD testing. Industry leaders such as Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., and Amgen Inc. are renowned for their continuous innovation in diagnostic technologies. Collaborative efforts between organizations like ARUP Laboratories and AstraZeneca PLC are fostering an environment where clinical research and practical applications converge seamlessly.

Furthermore, advancements are not confined to large conglomerates. Entities such as Asuragen Inc. by Bio-Techne Corporation and Bio-Rad Laboratories, Inc. are instrumental in strengthening the technological underpinnings of MRD testing through the development of novel reagents and kits. This innovation is echoed by the efforts of Bristol-Myers Squibb Company and C2I Genomics Inc., which are integrating multifaceted data analytics with strategic clinical insight.

Smaller, yet highly specialized companies including Cergentis B.V., Exact Sciences Corporation, and F. Hoffmann-La Roche Ltd. have also made significant contributions. The competitive landscape is further enriched by the strategic maneuvers of Genetron Holdings Limited and GRAIL, LLC by Illumina, Inc., which combine deep clinical knowledge with state-of-the-art technology to push the boundaries of diagnostic accuracy.

Additional momentum is provided by the contributions of Guardant Health, Inc. and Integrated DNA Technologies, Inc., who consistently strive to refine MRD detection capabilities. Invivoscribe, Inc. and Kite Pharma, Inc. by Gilead Sciences, Inc. complement these efforts by advancing the integration of MRD insights into therapeutic regimes. Not to be overlooked, Laboratory Corporation of America Holdings, Mdxhealth BV, and MedGenome Inc. continue to drive operational efficiencies and accuracy in test outcomes. Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., and NeoGenomics Laboratories, Inc. add further depth by offering specialized services that cater to increasingly diverse oncological profiles. Prominent companies such as OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc. fortify the industry's foundation with consistent innovation and a commitment to improved patient outcomes.

The report delves into recent significant developments in the Minimal Residual Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., Amgen Inc., ARUP Laboratories, AstraZeneca PLC, Asuragen Inc. by Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, C2I Genomics Inc., Cergentis B.V., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Genetron Holdings Limited, GRAIL, LLC by Illumina, Inc., Guardant Health, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., Kite Pharma, Inc. by Gilead Sciences, Inc., Laboratory Corporation of America Holdings, Mdxhealth BV, MedGenome Inc, Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., NeoGenomics Laboratories, Inc., OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc.. Actionable Recommendations for Industry Leaders

For decision-makers and industry leaders aiming to navigate the competitive landscape of MRD testing, it is essential to develop a strategic roadmap that encompasses both technological innovation and market adaptability. Continuous investment in research and development is of paramount importance, as it enables the refinement of detection techniques and the expansion of clinical applications. Leaders must prioritize partnerships with academic research institutions and regulatory bodies to stay abreast of evolving standards and incorporate best practices into their operational framework.

Embracing digital transformation is also critical. The modernization of diagnostic workflows through automation and enhanced data analytics can significantly reduce turnaround times and improve test accuracies. Adopting cloud-based platforms and integrating artificial intelligence algorithms are also pivotal in managing large volumes of data and drawing actionable insights that can shape patient management strategies. Organizations should not only invest in state-of-the-art instrumentation but also ensure that their teams are well-trained to harness the full potential of these technologies.

In addition to technological investments, a focus on strategic geographic expansion is advised. Tailoring product offerings to meet the specific needs of diverse regional markets can unlock new growth avenues. Leaders must align their strategies with local healthcare policies and invest in market research that elucidates regional trends, competitive landscapes, and regulatory requirements. Such an approach will facilitate the customization of MRD solutions to serve both mature markets and rapidly developing regions.

Collaboration is a powerful tool in this competitive sector. It is recommended that industry leaders foster alliances with companies that offer complementary capabilities. This can lead to the development of integrated diagnostic pathways which can in turn elevate clinical outcomes. Furthermore, a customer-centric approach that emphasizes transparency and direct engagement with end-users, including diagnostic laboratories and hospitals, will build trust and secure long-term partnerships.

Finally, maintaining an agile posture will be the linchpin for sustained success. Leaders need to continuously monitor market dynamics and adapt their strategies in response to shifts in technology, regulatory policies, and competitive pressures. By proactively identifying emerging trends and potential challenges, companies can position themselves as frontrunners in this rapidly evolving domain.

Conclusion and Future Outlook

The landscape of MRD testing is characterized by rapid innovation, evolving technological capabilities, and a deepening understanding of disease biology. This diagnostic technique continues to gain prominence for its critical role in managing complex oncological profiles. By integrating advanced methodologies such as flow cytometry, next-generation sequencing, and polymerase chain reaction, the industry is seeing unprecedented improvements in test accuracy and clinical outcomes.

The interplay between multiple market segments-from product types to end-user verticals-has created a dynamic environment where innovation and clinical application feed directly into one another. Regional insights further illuminate how localized regulatory frameworks and healthcare infrastructures are adjusting to incorporate MRD testing in routine clinical practice. Meanwhile, leading companies across the spectrum are setting benchmarks in technological advancement and operational excellence.

As the industry moves forward, sustained collaboration between technology developers, regulatory authorities, and clinical practitioners will be crucial. This will not only help in further refining the diagnostic capabilities of MRD testing but also in ensuring that these advancements translate into improved patient care. The strategic actions taken today are the cornerstones for a more responsive and effective diagnostic future.

In summary, the continued evolution of MRD testing stands as a testament to the power of innovation in transforming healthcare. The integration of sophisticated diagnostic tools into conventional treatment protocols is driving a shift towards more precise, personalized, and proactive patient care. The insights drawn from market trends, segmentation dynamics, and regional performance emphasize the necessity for a balanced approach that fuses advanced technology with on-ground clinical realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for early detection and accurate prognostic assessment
      • 5.1.1.2. Rising investments in precision medicine drive the focus on personalized minimal residual disease tests
      • 5.1.1.3. Innovations in diagnostic technology propelling the growth of minimal residual disease testing
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with testing and equipment
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding portfolio by researching and integrating minimal residual disease testing technologies into multi-disease diagnostics solutions
      • 5.1.3.2. Develop partnerships with biotechnology firms to innovate and engineer more effective testing kits for minimal residual disease detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complication in regulatory and lengthy approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Advancements in instruments for minimal residual disease testing catalyzing precision in oncology diagnostics
    • 5.2.2. End-User Vertical: The role of academic and research institutes in the advancement of minimal residual disease testing technologies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Minimal Residual Disease Testing Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Kits
  • 6.4. Software & Services

7. Minimal Residual Disease Testing Market, by Test Techniques

  • 7.1. Introduction
  • 7.2. Flow Cytometry
  • 7.3. Next-Generation Sequencing (NGS)
  • 7.4. Polymerase Chain Reaction (PCR)

8. Minimal Residual Disease Testing Market, by Application Areas

  • 8.1. Introduction
  • 8.2. Leukemia
  • 8.3. Lymphoma
  • 8.4. Multiple Myeloma
  • 8.5. Solid Tumors

9. Minimal Residual Disease Testing Market, by End-User Vertical

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biopharmaceutical Companies
  • 9.4. Diagnostic Laboratories
  • 9.5. Hospitals

10. Americas Minimal Residual Disease Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Minimal Residual Disease Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Minimal Residual Disease Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Tempus unveils innovative MRD testing portfolio to enhance personalized cancer care and treatment development
    • 13.3.2. Veracyte Expands cancer care reach with USD 70 million acquisition of C2i Genomics for advanced MRD capabilities
    • 13.3.3. Allogene Therapeutics and Foresight Diagnostics Forge partnership for innovative MRD-based diagnostic in LBCL ALPHA3 Trial
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptive Biotechnologies Corporation
  • 2. Agilus Diagnostics Ltd.
  • 3. Amgen Inc.
  • 4. ARUP Laboratories
  • 5. AstraZeneca PLC
  • 6. Asuragen Inc. by Bio-Techne Corporation
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. C2I Genomics Inc.
  • 10. Cergentis B.V.
  • 11. Exact Sciences Corporation
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Genetron Holdings Limited
  • 14. GRAIL, LLC by Illumina, Inc.
  • 15. Guardant Health, Inc.
  • 16. Integrated DNA Technologies, Inc.
  • 17. Invivoscribe, Inc.
  • 18. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 19. Laboratory Corporation of America Holdings
  • 20. Mdxhealth BV
  • 21. MedGenome Inc
  • 22. Mission Bio, Inc.
  • 23. Myriad Genetics, Inc.
  • 24. Natera Inc.
  • 25. NeoGenomics Laboratories, Inc.
  • 26. OPKO Health, Inc.
  • 27. Quest Diagnostics incorporated
  • 28. Sysmex Corporation
  • 29. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET MULTI-CURRENCY
  • FIGURE 2. MINIMAL RESIDUAL DISEASE TESTING MARKET MULTI-LANGUAGE
  • FIGURE 3. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
  • FIGURE 4. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MINIMAL RESIDUAL DISEASE TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
  • TABLE 193. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 194. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024